RMD

ResMed
D

RMD

Arincen97/100B

ResMed stock buybacks 1993–2027

ResMed spent 936.38M USD buying back its shares in Q1 FY2027, the three months to 30 September 2026, up 524.2% on the same quarter a year before. ResMed spent 1.99B USD buying back its shares over the last twelve months, up 396.6% on the twelve months before. In fiscal year 2026 it spent 700.04M USD, up 133.3% on the year before.

Last updated 6 Nov 2026 · Next report 28 Jan 2027

Stock buybacks

Growth

Fiscal yearPeriod endingStock buybacksGrowthDividends paidFree cash flow
TTM30 Sept 20261.99B+396.57%619.44M2.85B
FY202630 Jun 2026700.04M+133.33%349.66M1.65B
FY202530 Jun 2025300.03M+100.00%310.88M1.66B
FY202430 Jun 2024150.01M—282.32M1.29B
FY202330 Jun 20230.00—258.28M559.30M
FY202230 Jun 20220.00—245.34M195.11M
FY202130 Jun 20210.00—226.71M619.89M
FY202030 Jun 20200.00-100.00%225.09M696.32M
FY201930 Jun 201922.84M-57.54%211.71M381.71M
FY201830 Jun 201853.80M—199.50M433.57M
FY201730 Jun 20170.00-100.00%186.35M342.58M
FY201630 Jun 2016102.06M-36.33%168.13M480.10M
FY201530 Jun 2015160.30M-20.71%157.26M311.24M
FY201430 Jun 2014202.17M+8.54%141.52M310.11M
FY201330 Jun 2013186.26M-52.58%97.20M331.04M
FY201230 Jun 2012392.74M+140.44%0.00322.05M
FY201130 Jun 2011163.34M+24.61%0.00208.19M
FY201030 Jun 2010131.08M+91.10%0.00126.57M
FY200930 Jun 200968.59M-28.96%0.00124.66M
FY200830 Jun 200896.56M+4,515.54%0.0062.06M
FY200730 Jun 20072.09M—0.0013.55M
FY200630 Jun 20060.00-100.00%0.00-3.72M
FY200530 Jun 200510.97M-42.37%0.0031.39M
FY200430 Jun 200419.03M+437.18%0.0019.30M
FY200330 Jun 20033.54M-55.01%0.0033.65M
FY200230 Jun 20027.87M—0.007.46M
FY200130 Jun 20010.00—0.002.06M
FY200030 Jun 20000.00—0.004.11M
FY199930 Jun 19990.00—0.00-4.30M
FY199830 Jun 19980.00—0.00-5.00M
FY199730 Jun 19970.00—0.005.50M
FY199630 Jun 19960.00—0.002.00M
FY199530 Jun 19950.00-100.00%0.00-1.10M
FY199430 Jun 1994300.00K—200.00K1.30M
FY199330 Jun 19930.00—0.00700.00K

Figures in USD. Free cash flow is operating cash flow less capital expenditure. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

The money spent buying back the company's own shares in each period, from the cash flow statement.

See also:Revenue,Net income,EPS,Shares outstanding,Operating income,Cash on hand,Total debt,Free cash flow,Cash flow

Common questions about ResMed's buybacks

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.